BONN Dialysis renal and CARDiovascular disease biobank, BONDCARD

BONN Dialysis renal and CARDiovascular disease biobank, BONDCARD - BONDCARD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040315

Enrollment

300

Registered

2026-06-09

Start date

2026-06-11

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dialysis associated cardiovascular events.

Interventions

Group 1: Primary Project Objective: The aim of this biobank is to identify predictive markers for cardiovascular and renal events in dialysis-dependent patients through molecular analyses of blood, ur

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Chronic kidney disease stage V Treatment with hemodialysis and peritoneal dialysis

Exclusion criteria

Exclusion criteria: Lack of capacity to give informed consent Insufficient knowledge of the German language, making consent without an interpreter impossible

Design outcomes

Primary

Measure	Time frame
Analytical methods for the main research questions (exploratory approach): Metabolomic, proteomic, and transcriptomic analyses of patient samples are planned. The results of these investigations will be experimentally validated. Exact definition of the endpoints: From a clinical perspective, the endpoints are the occurrence (or new onset) of cardiovascular events: Coronary artery disease: - Initial diagnosis - Revascularization - Acute coronary syndrome - STEMI -NSTEMI - Unstable angina pectoris - Newly diagnosed heart failure with reduced ejection fraction - Newly diagnosed heart failure with preserved ejection fraction - Hospitalization due to heart failure Aortic aneurysm - Initial diagnosis - Progression on imaging studies - Dissection / rupture - Surgical / interventional treatment Aortic valve stenosis -Initial diagnosis -Progression on imaging studies -Hospitalization due to decompensation -Surgical / interventional treatment Atrial fibrillation -Initial diagnosis -Hospitalization due to decompensation -Intensification of antiarrhythmic therapy -Catheter ablation -Recurrence Residual renal function Dialysis-specific vascular complications Arteriovenous fistula complications Death from any cause -Cardiovascular death -Renal death	—

Measure

Time frame

Analytical methods for the main research questions (exploratory approach): Metabolomic, proteomic, and transcriptomic analyses of patient samples are planned. The results of these investigations will be experimentally validated. Exact definition of the endpoints: From a clinical perspective, the endpoints are the occurrence (or new onset) of cardiovascular events: Coronary artery disease: - Initial diagnosis - Revascularization - Acute coronary syndrome - STEMI -NSTEMI - Unstable angina pectoris - Newly diagnosed heart failure with reduced ejection fraction - Newly diagnosed heart failure with preserved ejection fraction - Hospitalization due to heart failure Aortic aneurysm - Initial diagnosis - Progression on imaging studies - Dissection / rupture - Surgical / interventional treatment Aortic valve stenosis -Initial diagnosis -Progression on imaging studies -Hospitalization due to decompensation -Surgical / interventional treatment Atrial fibrillation -Initial diagnosis -Hospitalization due to decompensation -Intensification of antiarrhythmic therapy -Catheter ablation -Recurrence Residual renal function Dialysis-specific vascular complications Arteriovenous fistula complications Death from any cause -Cardiovascular death -Renal death

—

Countries

Germany

Contacts

Public ContactAndreas Zietzer

Universitätsklinikum Bonn

andreas.zietzer@ukbonn.de+49 228 287 25108

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026